TY  - JOUR
AU  - Markovic, M
AU  - Knezevic, N
AU  - Momčilović, Miljana
AU  - Grgurić-Šipka, Sanja
AU  - Harhaji-Trajkovic, Ljubica
AU  - Trajković, Vladimir S.
AU  - Stojkovic, MM
AU  - Sabo, Tibor
AU  - Miljković, Đorđe
PY  - 2005
UR  - https://cherry.chem.bg.ac.rs/handle/123456789/718
AB  - There has been a continuing effort for the discovery of novel platinum(IV)-based antitumor compounds with better therapeutic performances than cisplatin. In the present work, the anticancer action of recently synthesized Pt(IV)-based complex [Pt(HPxSC)Cl-3] was investigated using rat and human astrocytoma cell lines C6 and U251. [Pt(HPxSC)Cl-3] markedly reduced the number of cultured astrocytoma Cells (IC50, 80 mu M), as determined by crystal violet assay. The Pt(IV) complex induced apoptotic death of tumor cells, as flow cytometry analysis of the propidium iodide-stained cellular DNA revealed approx. 30% of hypodiploid cells in [Pt(HPxSC)Cl-3]-treated astrocytoma cell cultures. On the other hand, [Pt(HPxSC)Cl-3] at 200 mu M did not affect the viability of rat primary astrocytes, unlike the established anticancer drug cisplatin, which displayed high toxicity toward both astrocytoma cells (IC50, 15 mu M) and primary astrocytes (IC50, 20 mu M). Moreover, [Pt(HPxSC)Cl-3] at 100 mu M did not interfere with the ability of rat peritoneal macrophages to produce important antitumor molecules nitric oxide and tumor necrosis factor-a. Finally, we assessed the ability of [Pt(HPxSC)Cl-3] to restrain growth of some bacterial and yeast strains, but it showed rather limited antimicrobial activity. (c) 2005 Elsevier B.V. All rights reserved.
PB  - Elsevier Science Bv, Amsterdam
T2  - European Journal of Pharmacology
T1  - [Pt(HPxSC)Cl-3], a novel platinum(IV) compound with anticancer properties
VL  - 517
IS  - 1-2
SP  - 28
EP  - 34
DO  - 10.1016/j.ejphar.2005.05.038
ER  - 

@article{
author = "Markovic, M and Knezevic, N and Momčilović, Miljana and Grgurić-Šipka, Sanja and Harhaji-Trajkovic, Ljubica and Trajković, Vladimir S. and Stojkovic, MM and Sabo, Tibor and Miljković, Đorđe",
year = "2005",
abstract = "There has been a continuing effort for the discovery of novel platinum(IV)-based antitumor compounds with better therapeutic performances than cisplatin. In the present work, the anticancer action of recently synthesized Pt(IV)-based complex [Pt(HPxSC)Cl-3] was investigated using rat and human astrocytoma cell lines C6 and U251. [Pt(HPxSC)Cl-3] markedly reduced the number of cultured astrocytoma Cells (IC50, 80 mu M), as determined by crystal violet assay. The Pt(IV) complex induced apoptotic death of tumor cells, as flow cytometry analysis of the propidium iodide-stained cellular DNA revealed approx. 30% of hypodiploid cells in [Pt(HPxSC)Cl-3]-treated astrocytoma cell cultures. On the other hand, [Pt(HPxSC)Cl-3] at 200 mu M did not affect the viability of rat primary astrocytes, unlike the established anticancer drug cisplatin, which displayed high toxicity toward both astrocytoma cells (IC50, 15 mu M) and primary astrocytes (IC50, 20 mu M). Moreover, [Pt(HPxSC)Cl-3] at 100 mu M did not interfere with the ability of rat peritoneal macrophages to produce important antitumor molecules nitric oxide and tumor necrosis factor-a. Finally, we assessed the ability of [Pt(HPxSC)Cl-3] to restrain growth of some bacterial and yeast strains, but it showed rather limited antimicrobial activity. (c) 2005 Elsevier B.V. All rights reserved.",
publisher = "Elsevier Science Bv, Amsterdam",
journal = "European Journal of Pharmacology",
title = "[Pt(HPxSC)Cl-3], a novel platinum(IV) compound with anticancer properties",
volume = "517",
number = "1-2",
pages = "28-34",
doi = "10.1016/j.ejphar.2005.05.038"
}

Markovic, M., Knezevic, N., Momčilović, M., Grgurić-Šipka, S., Harhaji-Trajkovic, L., Trajković, V. S., Stojkovic, M., Sabo, T.,& Miljković, Đ.. (2005). [Pt(HPxSC)Cl-3], a novel platinum(IV) compound with anticancer properties. in European Journal of Pharmacology
Elsevier Science Bv, Amsterdam., 517(1-2), 28-34.
https://doi.org/10.1016/j.ejphar.2005.05.038

Markovic M, Knezevic N, Momčilović M, Grgurić-Šipka S, Harhaji-Trajkovic L, Trajković VS, Stojkovic M, Sabo T, Miljković Đ. [Pt(HPxSC)Cl-3], a novel platinum(IV) compound with anticancer properties. in European Journal of Pharmacology. 2005;517(1-2):28-34.
doi:10.1016/j.ejphar.2005.05.038 .

Markovic, M, Knezevic, N, Momčilović, Miljana, Grgurić-Šipka, Sanja, Harhaji-Trajkovic, Ljubica, Trajković, Vladimir S., Stojkovic, MM, Sabo, Tibor, Miljković, Đorđe, "[Pt(HPxSC)Cl-3], a novel platinum(IV) compound with anticancer properties" in European Journal of Pharmacology, 517, no. 1-2 (2005):28-34,
https://doi.org/10.1016/j.ejphar.2005.05.038 . .

TY  - JOUR
AU  - Kaludjerovic, GN
AU  - Miljković, Đorđe
AU  - Momčilović, Miljana
AU  - Djinovic, VM
AU  - Stojkovic, MM
AU  - Sabo, Tibor
AU  - Trajković, Vladimir S.
PY  - 2005
UR  - https://cherry.chem.bg.ac.rs/handle/123456789/719
AB  - The anticancer activity of platinum complexes has been known since the discovery of classical Pt(II)-based drug cisplatin. However, Pt(IV) complexes have greater inertness than corresponding Pt(II) complexes, thus allowing the oral administration and reducing the toxicity associated with platinum-based chemotherapy. Here, we describe the in vitro antitumor activity of some novel Pt(IV)-based agents against mouse fibrosarcoma L929 cells and human astrocytoma U251 cells. The cytotoxicity of 2 Pt(IV) complexes with bidentate ethylenediamine-N,N'-di-3-propanoato esters was found to be markedly higher than that of their Pt(II) counterparts and comparable to the antitumor action of cisplatin. In contrast to cisplatin, which caused oxidative stress-independent apoptotic cell death of tumor cells, these Pt(IV) complexes induced oxygen radical-mediated tumor cell necrosis. Importantly, the cytotoxic action of novel Pt(IV) complexes was markedly more rapid than that of cisplatin, indicating their potential usefulness in anticancer therapy. (C) 2005 Wiley-Liss, Inc.
PB  - Wiley, Hoboken
T2  - International Journal of Cancer
T1  - Novel platinum(IV) complexes induce rapid tumor cell death in vitro
VL  - 116
IS  - 3
SP  - 479
EP  - 486
DO  - 10.1002/ijc.21080
ER  - 

@article{
author = "Kaludjerovic, GN and Miljković, Đorđe and Momčilović, Miljana and Djinovic, VM and Stojkovic, MM and Sabo, Tibor and Trajković, Vladimir S.",
year = "2005",
abstract = "The anticancer activity of platinum complexes has been known since the discovery of classical Pt(II)-based drug cisplatin. However, Pt(IV) complexes have greater inertness than corresponding Pt(II) complexes, thus allowing the oral administration and reducing the toxicity associated with platinum-based chemotherapy. Here, we describe the in vitro antitumor activity of some novel Pt(IV)-based agents against mouse fibrosarcoma L929 cells and human astrocytoma U251 cells. The cytotoxicity of 2 Pt(IV) complexes with bidentate ethylenediamine-N,N'-di-3-propanoato esters was found to be markedly higher than that of their Pt(II) counterparts and comparable to the antitumor action of cisplatin. In contrast to cisplatin, which caused oxidative stress-independent apoptotic cell death of tumor cells, these Pt(IV) complexes induced oxygen radical-mediated tumor cell necrosis. Importantly, the cytotoxic action of novel Pt(IV) complexes was markedly more rapid than that of cisplatin, indicating their potential usefulness in anticancer therapy. (C) 2005 Wiley-Liss, Inc.",
publisher = "Wiley, Hoboken",
journal = "International Journal of Cancer",
title = "Novel platinum(IV) complexes induce rapid tumor cell death in vitro",
volume = "116",
number = "3",
pages = "479-486",
doi = "10.1002/ijc.21080"
}

Kaludjerovic, G., Miljković, Đ., Momčilović, M., Djinovic, V., Stojkovic, M., Sabo, T.,& Trajković, V. S.. (2005). Novel platinum(IV) complexes induce rapid tumor cell death in vitro. in International Journal of Cancer
Wiley, Hoboken., 116(3), 479-486.
https://doi.org/10.1002/ijc.21080

Kaludjerovic G, Miljković Đ, Momčilović M, Djinovic V, Stojkovic M, Sabo T, Trajković VS. Novel platinum(IV) complexes induce rapid tumor cell death in vitro. in International Journal of Cancer. 2005;116(3):479-486.
doi:10.1002/ijc.21080 .

Kaludjerovic, GN, Miljković, Đorđe, Momčilović, Miljana, Djinovic, VM, Stojkovic, MM, Sabo, Tibor, Trajković, Vladimir S., "Novel platinum(IV) complexes induce rapid tumor cell death in vitro" in International Journal of Cancer, 116, no. 3 (2005):479-486,
https://doi.org/10.1002/ijc.21080 . .

TY  - JOUR
AU  - Djinovic, V
AU  - Momčilović, Miljana
AU  - Grgurić-Šipka, Sanja
AU  - Trajković, Vladimir S.
AU  - Stojkovic, MM
AU  - Miljković, Đorđe
AU  - Sabo, Tibor
PY  - 2004
UR  - https://cherry.chem.bg.ac.rs/handle/123456789/672
AB  - A novel class of ruthenium (111) complexes of formulas K[Ru(sar)(2)Cl-2] - 1/2HO and K-2[Ru(dmgly)Cl-4] . 1/2H(2)O, containing biden2 tate chelates N-methylglycine (sarcosine, sar) or N,N-dimethylglycine (dnigly) and additional chloro ligands were synthesized. The complexes have been obtained by direct reaction of ruthenium(III) chloride with corresponding bidentate ligand followed by addition of base (KOH). These new complexes were characterized by elemental analysis, IR and electronic absorption spectroscopy. As astrocytomas, the most common of all brain tumors, are still very difficult to treat, we examined the influence of newly synthesized ruthenium-based complexes, as well as the earlier synthesized analogue platinum(IV) complexes [Pt(dmglY)(2)Cl-2], [Pt(sar)(2)Br-2] and [Pt(dmgly)(2)Br-2] on rat astrocytoma C6 cells in vitro. Among these complexes only K-2[Ru(dmglY)Cl-4].2H(2)O and [Pt(dMgIY)(2)Br-2] markedly inhibited the viability of non-confluent C6 cells. Furthermore, only complex K-2[Ru(dmgly)Cl4] .2H20 was able to reduce viability in confluent C6 cultures. Importantly, this complex was not toxic to primary rat astrocytes or macrophages. Having in mind that appropriate chemotherapy should be effective against tumor cells without harming normal tissues, complex K,[Ru(dmglY)Cl-4] - 2H(2)O could be a promising agent for developing therapeutics against astrocytomas. (C) 2004 Elsevier Inc. All rights reserved.
PB  - Elsevier Science Inc, New York
T2  - Journal of Inorganic Biochemistry
T1  - Novel ruthenium complex K-2[Ru(dmgly)Cl-4] center dot 2H(2)O is toxic to C6 astrocytoma cell line, but not to primary rat astrocytes
VL  - 98
IS  - 12
SP  - 2168
EP  - 2173
DO  - 10.1016/j.jinorgbio.2004.10.007
ER  - 

@article{
author = "Djinovic, V and Momčilović, Miljana and Grgurić-Šipka, Sanja and Trajković, Vladimir S. and Stojkovic, MM and Miljković, Đorđe and Sabo, Tibor",
year = "2004",
abstract = "A novel class of ruthenium (111) complexes of formulas K[Ru(sar)(2)Cl-2] - 1/2HO and K-2[Ru(dmgly)Cl-4] . 1/2H(2)O, containing biden2 tate chelates N-methylglycine (sarcosine, sar) or N,N-dimethylglycine (dnigly) and additional chloro ligands were synthesized. The complexes have been obtained by direct reaction of ruthenium(III) chloride with corresponding bidentate ligand followed by addition of base (KOH). These new complexes were characterized by elemental analysis, IR and electronic absorption spectroscopy. As astrocytomas, the most common of all brain tumors, are still very difficult to treat, we examined the influence of newly synthesized ruthenium-based complexes, as well as the earlier synthesized analogue platinum(IV) complexes [Pt(dmglY)(2)Cl-2], [Pt(sar)(2)Br-2] and [Pt(dmgly)(2)Br-2] on rat astrocytoma C6 cells in vitro. Among these complexes only K-2[Ru(dmglY)Cl-4].2H(2)O and [Pt(dMgIY)(2)Br-2] markedly inhibited the viability of non-confluent C6 cells. Furthermore, only complex K-2[Ru(dmgly)Cl4] .2H20 was able to reduce viability in confluent C6 cultures. Importantly, this complex was not toxic to primary rat astrocytes or macrophages. Having in mind that appropriate chemotherapy should be effective against tumor cells without harming normal tissues, complex K,[Ru(dmglY)Cl-4] - 2H(2)O could be a promising agent for developing therapeutics against astrocytomas. (C) 2004 Elsevier Inc. All rights reserved.",
publisher = "Elsevier Science Inc, New York",
journal = "Journal of Inorganic Biochemistry",
title = "Novel ruthenium complex K-2[Ru(dmgly)Cl-4] center dot 2H(2)O is toxic to C6 astrocytoma cell line, but not to primary rat astrocytes",
volume = "98",
number = "12",
pages = "2168-2173",
doi = "10.1016/j.jinorgbio.2004.10.007"
}

Djinovic, V., Momčilović, M., Grgurić-Šipka, S., Trajković, V. S., Stojkovic, M., Miljković, Đ.,& Sabo, T.. (2004). Novel ruthenium complex K-2[Ru(dmgly)Cl-4] center dot 2H(2)O is toxic to C6 astrocytoma cell line, but not to primary rat astrocytes. in Journal of Inorganic Biochemistry
Elsevier Science Inc, New York., 98(12), 2168-2173.
https://doi.org/10.1016/j.jinorgbio.2004.10.007

Djinovic V, Momčilović M, Grgurić-Šipka S, Trajković VS, Stojkovic M, Miljković Đ, Sabo T. Novel ruthenium complex K-2[Ru(dmgly)Cl-4] center dot 2H(2)O is toxic to C6 astrocytoma cell line, but not to primary rat astrocytes. in Journal of Inorganic Biochemistry. 2004;98(12):2168-2173.
doi:10.1016/j.jinorgbio.2004.10.007 .

Djinovic, V, Momčilović, Miljana, Grgurić-Šipka, Sanja, Trajković, Vladimir S., Stojkovic, MM, Miljković, Đorđe, Sabo, Tibor, "Novel ruthenium complex K-2[Ru(dmgly)Cl-4] center dot 2H(2)O is toxic to C6 astrocytoma cell line, but not to primary rat astrocytes" in Journal of Inorganic Biochemistry, 98, no. 12 (2004):2168-2173,
https://doi.org/10.1016/j.jinorgbio.2004.10.007 . .